These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 29425253)

  • 21. KCa3.1: a new player in progressive kidney disease.
    Huang C; Pollock CA; Chen XM
    Curr Opin Nephrol Hypertens; 2015 Jan; 24(1):61-6. PubMed ID: 25415613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homoarginine ameliorates diabetic nephropathy independent of nitric oxide synthase-3.
    Wetzel MD; Stanley K; Maity S; Madesh M; Bopassa JC; Awad AS
    Physiol Rep; 2021 Mar; 9(5):e14766. PubMed ID: 33713581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes.
    Ma G; Allen TJ; Cooper ME; Cao Z
    Kidney Int; 2004 Sep; 66(3):1090-8. PubMed ID: 15327403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
    Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
    Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Podocyte-specific chemokine (C-C motif) receptor 2 overexpression mediates diabetic renal injury in mice.
    You H; Gao T; Raup-Konsavage WM; Cooper TK; Bronson SK; Reeves WB; Awad AS
    Kidney Int; 2017 Mar; 91(3):671-682. PubMed ID: 27914709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of KCa3.1 potassium channels protects against cisplatin-induced acute kidney injury.
    Chen CL; Liao JW; Hu OY; Pao LH
    Arch Toxicol; 2016 Sep; 90(9):2249-2260. PubMed ID: 26438401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of catalpol on diabetic nephropathy in rats.
    Dong Z; Chen CX
    Phytomedicine; 2013 Aug; 20(11):1023-9. PubMed ID: 23746755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical role for osteopontin in diabetic nephropathy.
    Nicholas SB; Liu J; Kim J; Ren Y; Collins AR; Nguyen L; Hsueh WA
    Kidney Int; 2010 Apr; 77(7):588-600. PubMed ID: 20130530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the potassium channel KCa3.1 in diabetic nephropathy.
    Huang C; Pollock CA; Chen XM
    Clin Sci (Lond); 2014 Oct; 127(7):423-33. PubMed ID: 24963668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
    Zhou G; Cheung AK; Liu X; Huang Y
    Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The KCa3.1 blocker TRAM-34 inhibits proliferation of fibroblasts in paraquat-induced pulmonary fibrosis.
    Xie H; Lu J; Zhu Y; Meng X; Wang R
    Toxicol Lett; 2018 Oct; 295():408-415. PubMed ID: 30036685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy.
    Lin M; Yiu WH; Li RX; Wu HJ; Wong DW; Chan LY; Leung JC; Lai KN; Tang SC
    Kidney Int; 2013 May; 83(5):887-900. PubMed ID: 23423259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of KCa3.1: A novel target to treat TGF-β1 induced conjunctival fibrosis.
    Anumanthan G; Wilson PJ; Tripathi R; Hesemann NP; Mohan RR
    Exp Eye Res; 2018 Feb; 167():140-144. PubMed ID: 29242028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease.
    Herrera M; Söderberg M; Sabirsh A; Valastro B; Mölne J; Santamaria B; Valverde AM; Guionaud S; Heasman S; Bigley A; Jermutus L; Rondinone C; Coghlan M; Baker D; Quinn CM
    Am J Physiol Renal Physiol; 2017 Apr; 312(4):F748-F759. PubMed ID: 27440778
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Black mulberry fruit extract alleviates streptozotocin-induced diabetic nephropathy in rats: targeting TNF-α inflammatory pathway.
    Abouzed TK; Sadek KM; Ghazy EW; Abdo W; Kassab MA; Hago S; Abdel-Wahab S; Mahrous EA; Abdel-Sattar E; Assar DH
    J Pharm Pharmacol; 2020 Nov; 72(11):1615-1628. PubMed ID: 32754951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy.
    Gao Q; Qin WS; Jia ZH; Zheng JM; Zeng CH; Li LS; Liu ZH
    Planta Med; 2010 Jan; 76(1):27-33. PubMed ID: 19639539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The protective role of fucosylated chondroitin sulfate, a distinct glycosaminoglycan, in a murine model of streptozotocin-induced diabetic nephropathy.
    Gomes CL; Leão CL; Venturotti C; Barreira AL; Guimarães G; Fonseca RJ; Fortunato RS; Mourão PA; Delgado AG; Takiya CM; Leite M
    PLoS One; 2014; 9(9):e106929. PubMed ID: 25192337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
    Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
    J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription.
    Liu IM; Tzeng TF; Liou SS; Chang CJ
    J Ethnopharmacol; 2009 Jul; 124(2):211-8. PubMed ID: 19397971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice.
    Tesch GH; Ma FY; Han Y; Liles JT; Breckenridge DG; Nikolic-Paterson DJ
    Diabetes; 2015 Nov; 64(11):3903-13. PubMed ID: 26180085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.